thought call
earn call theme similar across us biopharma good
result weaker guidanc fx headwinds/low price assumpt
said growth profil wors peer guidanc revenu
adjust ep underscor broad challeng legaci franchis biosimilar
threat new issu fundament concern yet stock
outperform far vs drg index suspect
share price stabil relat consist pattern good oper perform
despit variou headwind shareholder-friendli activ neither like
chang year bring much tougher set given unwilling
transform deal support growth lower likelihood anoth
tender offer acceler share repo diminish oper leverag given revenu
contract growth franchis aimovig repatha xgeva/prolia dont fill
hole left neupogen/neulasta/epo/enbrel/aranesp commerci challeng
view like overshadow look interest earli stage
pipelin includ bcma myeloma kra solid tumor
dont view even osteoporosi ou biosimilar portfolio differ
maker henc expect biosimilar eros risk narr persist
even worsen justifi equal weight rate pt
pipelin updat plan report data seven oncolog program
throughout although mani earli stage sever potenti
quickli transit pivot studi particular note bcma bite
multipl myeloma kra inhibitor solid tumor data
discuss also plan fda path market even
romosozumab recent receiv favor adcomm vote
model adjust follow call adjust revenu
forecast respect
similarli revis non-gaap ep estim
respect page detail
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight despit improv pipelin
committ y/i dividend increas
improv margin compani revenu growth
outlook remain modest contribut
evolocumab kyproli alreadi reflect
estim view risk/reward profil
balanc expect market look greater
revenu accler cost save
pipelin adopt faster
anticip increas visibl biosimilar
threat neulasta/enbrel unlik materi
near-to-short term
launch slower expect
increas certainti time
biosimilar enbrel neulasta launch like
come signific price discount brand
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
